

DT04 Rec **CT/PTO** 0 8 JUL 2004

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number	To be assigned 107500913
Filing Date	July 8, 2004
First Named Inventor	Van Gilst et al.
Group Art Unit	To be assigned 1653
Examiner Name	To be assigned Robert Mondesi
Attorney Docket Number	2578-6485US

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
RM		WO 00/61164	10-19-2000	Kenneth S. Warren Laboratories		
RM		WO 01/82952 A2	11-8-2001	Action Pharmaceuticals APS		
RM		WO 03/057242 A1	07-17-2003	Crucell Holland B.V.		

Examiner
Signature

/Robert Mondesi/

Date
Considered

07/10/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 2

Complete if Known

Application Number	To be assigned 10/500,913
Filing Date	July 8, 2004
First Named Inventor	Van Gilst et al.
Group Art Unit	To be assigned 1653
Examiner Name	To be assigned Robert Mondesi
Attorney Docket Number	2578-6485US

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
RM		PCT International Search Report, PCT/NL03/00011, dated April 24, 2003.	
RM		PCT International Preliminary Examination Report, PCT/NL03/00011, December 10, 2003.	

Examiner Signature	/Robert Mondesi/	Date Considered	07/10/2006
-----------------------	------------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



PTO/SB/08B(10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number	10/500,913
Filing Date	November 29, 2004
First Named Inventor	Van Gilst et al.
Group Art Unit	1615 1653
Examiner Name	Robert Mondesi
Attorney Docket Number	2578-6485US

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
RM		SILVERBERG et al., "The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations," Journal of the American College of Cardiology, June 2000, pp. 1737-1744, Vol. 35, No. 7.	
		MANCINI et al., "Erythropoietin improves exercise capacity in patients with heart failure," Circulation, 23 October 2001, pp. II.428, Vol. 104, No. 17 Supplement.	
		AKIMOTO et al., "Erythropoietin regulates vascular smooth muscle cell apoptosis by a phosphatidylinositol 3 kinase-dependent pathway," Kidney International, July 2000, pp. 269-282, Vol. 58, No. 1.	
		WESTENFELDER et al., "Anti-apoptotic, mitogenic and motogenic actions of erythropoietin on tubular cells protect renal function and accelerate recovery from ischemic acute renal failure in rats," Journal of Investigative Medicine, January 2001, pp. 59a, Vol. 49, No. 1.	
		ARCASOY et al., "Erythropoietin (EPO) stimulates angiogenesis in vivo and promotes wound healing," Blood, 16 November 2001, pp. 822a-823a, Vol. 98, No. 11, Part 1.	
		KRAUSE et al., "Recombinant human erythropoietin stimulates angiogenesis in a novel in vitro assay of human myocardial tissue," Journal of the American College of Cardiology, February 2001, pp. 236a, Vol. 37, No. 2, Supplement A.	

Examiner
Signature

/Robert Mondesi/

Date
Considered

07/10/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.